Fig. 7: Antagonizing MDSCs inhibits BrafV600E-induced immune-suppression and tumor advancement. | Nature Communications

Fig. 7: Antagonizing MDSCs inhibits BrafV600E-induced immune-suppression and tumor advancement.

From: Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors

Fig. 7

a Percentage of tumor-infiltrating myeloid immune cells (CD45+CD11b+) of CD45+ TILs in mPTC at 5w compared with wild-type littermates, analyzed by FlowJo, n = 3. b Quantification of whole leukocyte populations in thyroid glands of mPTC at 1 m, 2 m and 3 m by FlowJo, n = 4. c Percentage of G-MDSCs and M-MDSCs of CD45+ TILs in mPTC tumors at 1 m and 3 m, n = 4. d Relative CD8+ T cells/G-MDSCs of mPTC at 1 m or 3 m was plotted, n = 4. e IHC analysis of CD11b, Gr-1, S100A8, CD4 and CD8. Scale bars, 50μm. f Quantification of whole leukocyte populations in thyroid glands of mPTC-TAM induced with tamoxifen for 6 m and 12 m, n = 5. g, h FlowJo analysis of G-MDSCs, M-MDSCs, CD4+ T cells and CD8+ T cells of CD45+ TILs in mPTC-TAM tumors induced with tamoxifen for 6 m and 12 m (g), CD8+ T cells/G-MDSCs was plotted (h), n = 5. i Mice bearing tumors were treated with anti-IgG antibody or anti-Gr-1 antibody three times a week at age of 3w for 20d, and received daily oral doses of PLX4032 or vehicle for 20d. Tumor volumes and tumor weights were counted, n = 7. j Flow cytometric analysis of tumors underwent above treatments. Percentage of positive cells relative to total cells was plotted. MDSCs (upper) and CD8+ T cells/MDSCs (lower), n = 4. k IHC staining in four groups of mPTC from (i). Scale bars, 50μm. A representative of three independent experiments was shown (e, k). Data are shown as the mean ± s.d. (a, c, d, g–j). P values were calculated by unpaired two-tailed Student’s t test (a, c, d, g–j). Statistical source data are provided in Source Data.

Back to article page